OGN (Organon) Beginning Cash Position: $574 Mil (As of Mar. 2026)


OGN Organon & Co OGN
71 GF Score
Price $13.52
GF Value $14.54
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Organon Beginning Cash Position?

Organon OGN +0.22% 71 Beginning Cash Position is $574 Mil as of Mar. 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.54 (Fairly Valued). The stock has 10 warning signs investors should review.

Organon's Beginning Cash Position for the quarter that ended in Mar. 2026 was $574 Mil.

Organon's quarterly Beginning Cash Position increased from Sep. 2025 ($599 Mil) to Dec. 2025 ($672 Mil) but then declined from Dec. 2025 ($672 Mil) to Mar. 2026 ($574 Mil).

Organon's annual Beginning Cash Position declined from Dec. 2023 ($706 Mil) to Dec. 2024 ($693 Mil) and declined from Dec. 2024 ($693 Mil) to Dec. 2025 ($675 Mil).

Organon Beginning Cash Position Related Terms

Organon Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Organon's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon Beginning Cash Position Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 70.00 737.00 706.00 693.00 675.00

Organon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 675.00 547.00 599.00 672.00 574.00
OGN
71GF Score
Organon & Co OGN
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organon Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $574 Mil mean?
Organon (OGN) has a Beginning Cash Position of $574 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Organon and its competitors.
Is Organon's Beginning Cash Position too high?
Organon's current Beginning Cash Position is $574 Mil. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Beginning Cash Position compare to AMRN and SCLX?
Organon's Beginning Cash Position of $574 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Organon and its competitors. Organon's current Beginning Cash Position is $574 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.54, compared to a current price of $13.52 — trading 7% below its estimated fair value. The current Beginning Cash Position is $574 Mil. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Organon (OGN), the current Beginning Cash Position is $574 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of $13.52 is trading 7% below its estimated GF Value™ of $14.54. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Beginning Cash Position: $574 Mil
  • GF Value™: $14.54 vs. price of $13.52 (7% below fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score

Get the complete analysis for OGN

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.52
Price
$14.54
GF Value